Outpatient monitoring of CAR T-cell therapy reduces healthcare resource utilization and hospital days without impacting 30-day mortality, finds ASCO study.

This feature explores evolving management strategies for bone sarcomas, highlighting multidisciplinary treatment approaches ...

PVR demonstrated superiority versus VR in the ITT analysis population; benefits consistent across prespecified subgroups.

Using individual patient data from phase 2 and 3 trials, investigators analyzed the value of pathologic complete response vs ctDNA clearance after neoadjuvant immunotherapy or perioperative ...

Each additional hour per day of prolonged sedentary behavior is associated with a higher hazard of cancer death.

Low MAR consistently identified patients with more favorable long-term outcomes across subgroups. Preoperative monocyte-to-albumin ratio (MAR) independently predicted overall survival (OS) in patients ...

Investigators conducted a retrospective analysis to determine whether postmenopausal women with a history of breast cancer can safely receive vaginal estrogen.

Early low-dose lenalidomide significantly reduces mutational burden without increasing AML risk in non-transfusion-dependent del(5q) MDS.

In this study, researchers aimed to evaluate patterns of engagement with health-related content on social media among US adults both with and without chronic conditions.

A real-world analysis investigates the impact of concurrent GLP-1 RA use on long-term survival and the safety profile of patients with solid and hematologic malignancies receiving immune checkpoint ...

In this study, the researchers aimed to identify 5- and 10-year relative survival outcomes for individuals aged younger than 20 years at the time of a cancer diagnosis.

Tregzi (clinically known as Orca-T) is an allogeneic cellular immunotherapy consisting of purified regulatory and conventional T cells.